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Abstract
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved
survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered.
Methods The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non-muscle tissues were
investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B-Fc). Treatment with
sACVR2B-Fc was applied either only before the tumour formation or with continued treatment both before and after tumour
formation. The potential roles of muscle and non-muscle tissues in cancer cachexia were investigated in order to understand
the possible mechanisms of improved survival mediated by ACVR2 ligand blocking.
Results Blocking of ACVR2 ligands improved survival in tumour-bearing mice only when the mice were treated both before
and after the tumour formation. This occurred without effects on tumour growth, production of pro-inflammatory cytokines
or the level of physical activity. ACVR2 ligand blocking was associated with increased muscle (limb and diaphragm) mass and
attenuation of both hepatic protein synthesis and splenomegaly. Especially, the effects on the liver and the spleen were
observed independent of the treatment protocol. The prevention of splenomegaly by sACVR2B-Fc was not explained by
decreased markers of myeloid-derived suppressor cells. Decreased tibialis anterior, diaphragm, and heart protein synthesis
were observed in cachectic mice. This was associated with decreased mechanistic target of rapamycin (mTOR) colocalization
with late-endosomes/lysosomes, which correlated with cachexia and reduced muscle protein synthesis.
Conclusions The prolonged survival with continued ACVR2 ligand blocking could potentially be attributed in part to the
maintenance of limb and respiratory muscle mass, but many observed non-muscle effects suggest that the effect may be more
complex than previously thought. Our novel finding showing decreased mTOR localization in skeletal muscle with
lysosomes/late-endosomes in cancer opens up new research questions and possible treatment options for cachexia.
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Introduction
Cancer cachexia is a debilitating condition without an effec-
tive treatment. It is usually associated with marked loss of
muscle and fat mass, reduced physical activity and function,
decreased tolerance to cancer therapies and increased mor-
tality.1,2 Skeletal muscle has been an underappreciated tissue
in health and disease,3 but a growing body of evidence sug-
gests a beneficial role for treating muscle tissue in cachectic
conditions associated with different diseases, such as cancer.4
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Muscle wasting in cancer cachexia is a consequence of de-
creased muscle protein synthesis,5,6 impaired regeneration7
and/or increased protein degradation,6 but their relative im-
portance and mechanisms are not well known. One possible
mechanism for muscle wasting in cachexia is increased signal-
ling through activin receptor ligands, such as myostatin and
activins.8–11Myostatin and activins negatively regulate muscle
mass through binding to their receptors activin receptor type 2
(ACVR2) A and B.12,13 Blocking these ligands or their receptors
can increase muscle mass and prevent muscle wasting in vari-
ous animal models,12–16 but also in humans.17,18
Prevention of cancer associated cachexia by blocking
ACVR2 ligands with either soluble receptor (sACVR2B)9,16 or
neutralizing antibody against the receptors14 has previously
been shown to improve survival without an effect on primary
tumour growth in preclinical animal models. In addition,
many other strategies to prevent muscle loss in different
experimental models suggest causality between reduced
muscle loss and survival in cachexia. For example, inhibition
of NF-κB signalling reduced denervation- and Lewis lung
carcinoma (LLC) tumour-induced muscle loss which was
associated with improved survival rate.19 Blocking GDF15,
and consequently cachexia, significantly improved survival
in fibrosarcoma (HT-1080) and in LNCaP tumour-bearing
mice.20 Furthermore, preventing the loss of muscle mass in
C26 tumour-bearing mice by histone deacetylace inhibitor21
and by inhibiting TWEAK/Fn14 signalling in the tumour22
have prolonged survival.
If indeed treating cachexia and especially muscle loss by
strategies such as blocking ACVR2 ligands can improve sur-
vival in cancer, this may occur at least in part through
preventing the loss of respiratory muscle mass and func-
tion.23 However, also other factors, such as haematological
changes, acute phase response (APR), inflammatory cyto-
kines, and myeloid-derived suppressor cells (MDSCs), have
recently been identified as potential contributors to either
the development of cancer cachexia or to the poor prognosis
associated with it.24–28 The contribution of these factors to
the improved survival, when treating cachexia by blocking
of ACVR2 ligands, is unknown.
In the present study, we aimed to study the effects of
blocking ACVR2 ligands in a preclinical model of cancer
cachexia on both muscle and non-muscle tissues. Two differ-
ent treatment protocols were applied to compare the effects
of blocking ACVR2 ligands only before the tumour formation,
and thus increasing muscle size only prior to the onset of
cachexia, or continued treatment both before and after the
onset of cachexia. This comparison was performed to investi-
gate whether increased muscle mass alone before the onset
of cachexia is enough for the improved survival or if the con-
tinued treatment is crucial. We aimed to gain more insight
into the potential mechanisms of muscle wasting and the role
of non-muscle tissues in cancer cachexia, in order to under-
stand the sACVR2B-mediated improved survival.
Materials and methods
Animals
BALB/c (BALB/cAnNCrl) male mice aged 5–6 weeks (Charles
River Laboratories, Germany) were used in all experiments.
Mice were housed under standard conditions (temperature
22°C, 12:12 h light/dark cycle) with free access to food pellets
(R36; 4% fat, 55.7% carbohydrate, 18.5% protein, 3 kcal/g,
Labfor, Stockholm Sweden) and water.
The treatment of the animals was in strict accordance with
the European Convention for the protection of vertebrate
animals used for experimental and other scientific purposes.
The protocols were approved by the National Animal
Experiment Board, and all the experiments were carried out
in accordance with the guidelines of that committee (permit
number: ESAVI/10137/04.10.07/2014) and with the ethical
standards laid down in the 1964 Declaration of Helsinki and
its later amendments.
Tumour cell culture
Colon 26 carcinoma (C26) cells (provided by Dr Fabio Penna,
obtained from Prof. Mario P. Colombo and originally charac-
terized by Corbett et al.29) were maintained in complete
Dulbecco’s Modified Eagle’s Medium (high glucose,
GlutaMAX™ Supplement, pyruvate, Gibco™, Life Technologies)
supplemented with penicillin (100 U/mL), streptomycin
(100 μg/mL), and 10% FBS. Our pilot experiments showed
that injecting mice with C26 cells (5 × 105), resulted in
marked cachexia and considerably higher tumour gene ex-
pression of Activin A, Interleukin-6 (Il-6) and Myostatin in
comparison to our previously conducted experiment using
the LLC tumour model (Online Resource 1: Figure S1) with
the same number of cells injected (5 × 105), but larger tu-
mour15 (data not shown).
Experimental design
The mice were randomized into one of four groups (matched
by body weight): (i) healthy control mice (CTRL), (ii) C26
tumour-bearing mice receiving vehicle treatment throughout
the experiment (C26 + PBS), (iii) C26 tumour-bearing mice
receiving sACVR2B-Fc treatment before tumour formation
(until Day 1 after C26 cell inoculation) followed by vehicle
treatment until the end of the experiment (C26 + sACVR/
b), and (iv) C26 tumour-bearing mice receiving continued
sACVR2B-Fc treatment throughout the experiment
(C26 + sACVR/c). The experimental design and the treatment
protocols are shown in Figure 1. Body mass and food intake
of the mice were monitored daily in all the experiments.
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Survival experiment
The mice were followed until the predetermined humane
end-point criteria were fulfilled, or until 3 weeks after C26
cell inoculation at the latest, to investigate survival. The
end-point criteria combined the body mass loss and the over-
all condition of the mice. In the evaluation of the overall
health status of the mice, the following aspects were taken
into account in addition to the body mass loss: appearance
and posture (lack of grooming, piloerection, and hunched
posture), natural and provoked behaviour (inactivity, im-
paired locomotion, and reduced reactivity to external stim-
uli), and food intake/ability to eat and drink. Mice were
euthanized when two researchers confirmed the fulfilment
of the end-point criteria. During the experiment, seven mice
needed to be euthanized due to reasons unrelated to study
purposes (e.g. tumour ulceration or self-mutilation), and
three mice were excluded from analysis due to delayed
tumour growth. This did not have any major effect on
the results.
Short-term experiments
To study the potential mechanisms, another experiment was
conducted with a predetermined end-point at Day 11 after
C26 cell inoculation (Figure 1). This experiment was repeated
with three groups: CTRL, C26 + PBS and C26 + sACVR/c
groups in order to replicate the findings of the first short-
term experiment and to collect more samples and data for
further analysis.
Experimental treatments
An intraperitoneal injection of sACVR2B-Fc (5 mg/kg) or PBS
(100 μl) was administered twice a week, three times before
and three times after C26 cell inoculation (on Days -11, -7, -
3, 1, 5, and 9) in all experiments (Figure 1). On Day 0, mice
were anaesthetized by intraperitoneal administration of keta-
mine and xylazine (Ketaminol® and Rompun®, respectively)
and inoculated with 5 × 105 C26 cells in 100 μl of PBS (tu-
mour-bearing mice) or with an equal volume of vehicle
(PBS) only (CTRL) into the intrascapular subcutis.
The production of soluble ACVR2B
The ectodomain of ACVR2B was fused with an IgG1 Fc do-
main and the fusion protein was expressed in house in Chi-
nese hamster ovary cells grown in a suspension culture as
explained earlier in detail.30 The protein is similar but not
identical to that originally generated by Lee and colleagues.12
Home cage physical activity
Home cage physical activity was recorded by our validated
force plate system as previously described31,32 at baseline
and on Day 10 after C26 cell inoculation (22 h recording).
The mice were housed in pairs and the activity index of each
cage reflects the total locomotive activity in all directions (y,
x, and z axes) of the two mice housing the same cage (from
the same experimental group).
Figure 1 Schematic representation of the experimental design and the treatments. C26 cells were injected on Day 0, and sACVR2B-Fc or PBS vehicle
were administered on Days -11, -7, -3, 1, 5, and 9 in all experiments.
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Tissue collection
At the end of each experiment, the mice were anaesthetized
by an intraperitoneal injection of ketamine and xylazine
(Ketaminol® and Rompun®, respectively) and euthanized by
cardiac puncture followed by cervical dislocation. A sample
of the collected blood was taken to EDTA tubes for the anal-
ysis of basic haematology. The rest of the blood was collected
in serum collection tubes, and centrifuged at 2000 g for
10 min (Biofuge 13, Heraeus). The diaphragm, the heart,
tibialis anterior (TA), and gastrocnemius muscles, as well as
the liver, the spleen, epididymal fat pads, and the tumour
were rapidly excised, weighed, and snap-frozen in liquid ni-
trogen. The right TA and a sample of the spleen were embed-
ded in Tissue-Tek® O.C.T. compound and snap-frozen in
isopentane cooled with liquid nitrogen. All tissue masses
were normalized to the length of the tibia (TL, mm), which
was unaltered by the tumour or the continued sACVR2B-Fc
treatment, but slightly increased in the C26 + sACVR/b group
as compared to C26 + PBS (Online Resource 3: Figure S2).
Muscle protein synthesis: in vivo surface sensing of
translation
Muscle protein synthesis was analysed using surface sensing
of translation method33,34 as earlier in our laboratory.15,30,35
Briefly, on Day 11 after C26 cell inoculation, mice were anaes-
thetized and subsequently injected i.p. with 0.040 μmol/g
puromycin (Calbiochem, Darmstadt, Germany) dissolved in
200 μl of PBS. At exactly 25 min after puromycin administra-
tion, mice were euthanized by cardiac puncture followed by
cervical dislocation. The left TA muscle and the heart, the
diaphragm, as well as a sample of the median lobe of the liver
were isolated, weighed and snap-frozen in liquid nitrogen at
exactly 30, 35, and 40 min, respectively, after puromycin
administration.
Basic haematology
Basic haematology was analysed from whole blood (EDTA)
samples diluted 1:25 in saline solution with an automated
haematology analyser (Sysmex XP 300 analyzator Sysmex
Inc, Kobe, Japan). For the analysis of the platelet count,
whole blood was diluted 1:250 due to high platelet counts
in the samples.
Multiplex cytokine assay
A multiplex cytokine assay (Q-Plex Array 16-plex ELISA,
Quansys Biosciences, Logan, Utah, USA) was performed in
accordance with manufacturer’s instructions from 25 μl of
serum at 11 days post cancer cell inoculation.
RNA extraction, cDNA synthesis, and quantitative
real-time PCR
Total RNA was extracted from tumour, gastrocnemius, and
spleen samples using QIAzol and purified with RNeasy Univer-
sal Plus kit (Qiagen) according to manufacturer’s instructions
resulting in high quality RNA. RNA was reverse transcribed to
complementary DNA (cDNA) with iScriptTM Advanced cDNA
Synthesis Kit (Bio-Rad Laboratories) following kit instructions.
Real-time qPCR was performed according to standard proce-
dures using iQ SYBR Supermix (Bio-Rad Laboratories) and
CFX96 Real-Time PCR Detection System combined with CFX
Manager software (Bio-Rad Laboratories). Data analysis was
carried out by using efficiency corrected ΔΔCt method. Based
on the lowest variation between and within the groups of the
potential housekeeping genes (Rn18S, Gapdh, 36b4, or Tbp),
Tbp was selected for the spleen whereas 36b4 was chosen
for the tumour and the muscle. Primers used are listed in On-
line Resource 2: Supplementary methods (Table S1).
Protein extraction and content
Tibialis anterior (TA), diaphragm, heart, and liver samples
were homogenized in ice-cold buffer with proper protease
and phosphatase inhibitors and further treated as earlier30
with slight modifications. The samples were centrifuged at
500 g for 5 min at +4°C for the analysis of the protein synthe-
sis, and at 10 000 g for 10 min at +4°C for other analyses. To-
tal protein content was determined using the bicinchoninic
acid protein assay (Pierce, Thermo Scientific) with an auto-
mated KoneLab device (Thermo Scientific).
Citrate synthase activity assay
Citrate synthase activity was measured from TA, diaphragm,
and heart homogenates using a kit (Sigma-Aldrich) with an
automated KoneLab device (Thermo Scientific).
Western blotting
Western blot analysis was performed as previously de-
scribed.15,30,36 Briefly, tissue homogenates containing 30 μg
of protein were solubilized in Laemmli sample buffer and
heated at 95°C (except at 50°C for the analysis of OXPHOS
proteins) to denature proteins, separated by SDS-PAGE and
then transferred to PVDF membrane followed by overnight
probing with primary antibodies at +4°C. Proteins were visu-
alized by enhanced chemiluminescence using a ChemiDoc
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XRS device and quantified with Quantity One software ver-
sion 4.6.3 (Bio-Rad Laboratories, Hercules, California, USA).
In the case of the analysis of puromycin-incorporated pro-
teins and ubiquitinated proteins, the intensity of the whole
lane was quantified. Ponceau S staining and GAPDH were
used as loading controls and all the protein level results
were normalized to the mean of Ponceau S and GAPDH.
Antibodies used are listed in Online Resource 2: Supplemen-
tary methods.
Histology and immunohistochemistry
For histological analysis, 10 μm thick frozen sections were cut
from O.C.T.-embedded (Tissue-Tek) TA and spleen samples.
Antibodies used in the immunofluorescence analyses are
listed in Online Resource 2: Supplementary methods.
For mechanistic target of rapamycin (mTOR)-LAMP2
colocalization analysis, TA sections were air-dried and fixed
in 20°C acetone for 10 min. After PBS washes, sections
were blocked with 5% goat serum and 0.3% CHAPS in PBS
for 1 h, washed with PBS, and incubated overnight at +4°C
with primary antibodies against mTOR, dystrophin, and
LAMP2 diluted in PBS containing 0.5% BSA and 0.3% CHAPS.
After PBS washes, sections were incubated with secondary
antibodies (Goat anti-rabbit Alexa Fluor 555, Goat anti-mouse
Alexa Fluor 405 and Goat anti-rat Alexa Fluor 488) for 1 h at
room temperature, washed and mounted.
Spleen sections were stained using haematoxylin and eosin
for basic histology. For immunofluorescence staining, frozen
sections were air-dried for 15 min and fixed with 4% PFA
for 10 min, followed by washes with PBS. The sections were
blocked with 5% goat serum in PBS for 1 h, washed with
PBS, and incubated with primary antibodies against LY-6G
and LY-6C (GR-1) or CD11b diluted in 0.5% BSA in PBS at
+4°C overnight. After washing, the sections were incubated
with Alexa fluorochrome conjugated secondary antibody
(Goat anti-rat Alexa Fluor 488) diluted in 5% goat serum in
PBS for 1 h.
The samples were mounted with Mowiol-DABCO. Fluores-
cently labelled samples were imaged using Zeiss LSM 700
confocal microscope and analysed from 10 images (mTOR-
LAMP2) or from 6–11 images (CD11b and GR-1) in each sam-
ple using ImageJ. The colocalization of mTOR with LAMP2
was analysed according to Costes et al.37 using the
Colocalization Threshold plugin. All the steps were performed
blinded to the sample identification.
Statistical analyses
Differences in survival were analysed with the Kaplan–Meier
method [log-rank (Mantel-Cox) test]. Cox regression analysis
was used to determine factors predicting survival. The C26
cancer effect (CTRL vs. C26 + PBS or CTRL vs. C26 groups
pooled) was examined with Student’s t-test or non-
parametric Mann–Whitney U test, and the effect of
sACVR2B-Fc in the tumour-bearing groups with one-way anal-
ysis of variance or Kruskall–Wallis test followed by Holm–
Bonferroni corrected LSD or Mann–Whitney U post hoc tests,
respectively, when appropriate. Pearson correlation coeffi-
cient was used to analyse correlations. Statistical significance
was set at P < 0.05. All values are presented as means ± SEM
unless otherwise stated.
Results
Blocking activin receptor type 2B ligands improves
survival of C26 tumour-bearing mice
Mice treated with sACVR2B started to gain body mass soon
after the beginning of the treatment (Online Resource 3:
Figure S2). The body mass of the tumour-bearing mice
started to decrease after C26 cell inoculation. There was
no significant difference in the survival time between
C26 + PBS and C26 + sACVR/b groups (Figure 2A). However,
the survival was significantly improved when sACVR2B-Fc
administration was continued also after tumour formation
(Figure 2A).
To study the potential mechanisms underlying the im-
proved survival with only the continued sACVR2B-Fc ad-
ministration, another experiment was conducted.
Associations between the body mass change and survival
time were analysed with Cox regression analysis, which
revealed that especially the body weight change from
Day 10 to Day 11 after cancer cell inoculation predicted
survival (B = 1.82, P < 0.001). Thus, Day 11 was deter-
mined as the end-point for the second experiment to tar-
get the early phase of cachexia. At this time point,
vehicle treated tumour-bearing mice exhibited cachexia
manifested by significantly decreased body mass accom-
panied by lower TA, diaphragm, and adipose tissue mass
compared with healthy controls (Figure 2B–F, Body mass
in Online Resource 3: Figure S2). Both sACVR2B-Fc admin-
istered groups had significantly greater TA masses com-
pared with vehicle treated tumour-bearing controls, and
similar trend was also apparent in diaphragm (Figure 2C
and 2D). sACVR2B-Fc administration had no effect on ad-
ipose tissue mass when compared to the PBS-treated
mice, but discontinuation of the treatment seemed to re-
sult in more prominent fat wasting compared with the
continued treatment (ns) (Figure 2F). Increased fat
wasting together with non-significantly smaller muscle
masses compared with continued treatment protocol
probably explains why body mass had started to decrease
especially rapidly in C26 + sACVR/b group. Heart mass
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was unaffected by the tumour and the sACVR2B-Fc admin-
istration at this time point (Figure 2E), although mild car-
diac cachexia was observed in our pilot study at 2 weeks
after cancer cell inoculation (Online Resource 1: Figure
S1). During the last days of the experiment, all tumour-
bearing groups had reduced food intake compared to
healthy controls (Figure 2G).
Administration of sACVR2B-Fc had no effect on tu-
mour mass (Figure 2H). To find out if the mRNA expres-
sion of the potential cachexia-inducing factors was
nonetheless modulated by sACVR2B-Fc administration,
gene expressions were analysed from the tumours. Con-
sistent with no effects on tumour mass, sACVR2B-Fc ad-
ministration had no major effect on tumour Activin A
(Inhibin βA) mRNA expression, but it increased Il-6
mRNA expression independent of the treatment protocol
(Online Resource 3: Figure S2). In the gastrocnemius mus-
cles of the tumour-bearing mice, the mRNA expression of
Activin A slightly, but significantly decreased while Il-6
strongly increased and Myostatin (Gdf8) tended to increase
without an effect of the treatment (Online Resource 3:
Figure S2).
Muscle protein synthesis and mTOR signalling are
decreased in C26 cancer cachexia alongside
reduced mTOR localization to
lysosomes/late-endosomes
To clarify the mechanisms underlying C26 cancer-induced
muscle atrophy, muscle protein synthesis was analysed from
TA, diaphragm, and the heart. Tumour-bearing mice had
markedly blunted protein synthesis in all of these tissues
and especially in TA, whereas sACVR2B-Fc administration
had no effect (Figure 3A). The mTOR, a regulator of protein
synthesis, is at least in part regulated by its subcellular
Figure 2 The effects of sACVR2B-Fc administration on survival, tissue masses and food intake in C26 cancer cachexia. (A) A 3-week Kaplan–Meier sur-
vival curve (log-rank (Mantel-Cox) test). N = 6, 12, 8, and 9 in CTRL, C26 + PBS, C26 + sACVR/b, and C26 + sACVR/c, respectively. (B) Body mass and the
final tumour-free body mass, in the short-term experiment. There was a significant time × group interaction (P = 0.006, repeated measures ANOVA).
Masses of (C) tibialis anterior (TA), (D) diaphragm (DIA), (E) the heart, and (F) epididymal white adipose tissue (eWAT) normalized to the length of
the tibia in mm (TL) at 11 days after C26 cell inoculation. (G) Average food intake during Days 8–10 of the short term experiment, in which N = 3–4
cages/group, 2 mice/cage. (H) Tumour mass on Day 11 after C26 cell inoculation. *, ** and *** = P < 0.05, 0.01 and 0.001, respectively. CTRL vs.
C26 + PBS difference was analysed by Student’s t-test (B–G), and differences between the C26-groups with one-way ANOVA with Holm–Bonferroni
corrected LSD (B–H). Lines without vertical ends show a pooled effect: (D) sACVR2B-Fc combined and (G) C26-groups combined. N-sizes are depicted
in the bar graphs.
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localization: localization to the lysosomal/late-endosome
membrane is associated with mTOR activation.38,39 To ana-
lyse whether decreased muscle protein synthesis was associ-
ated with altered mTOR localization, TA cross-sections were
labelled with antibodies against mTOR and a lysosome/late-
endosome marker LAMP2. The results demonstrate that
colocalization of mTOR with LAMP2 was decreased in the
tumour-bearing mice compared with the control group and
restored by continued sACVR2B-Fc administration (Figure
3B), reflecting the levels of phosphorylation of ribosomal
protein S6, a marker of mTOR signalling (Figure 3C). Also
the phosphorylation of S6 kinase 1 at Thr389 was decreased
in the tumour-bearing mice without consistent restoration
by the continued sACVR2B-Fc treatment (Online Resource 4:
Figure S3). The total amount of mTOR analysed with western
blotting was similar between the groups (data not shown). In-
terestingly, mTOR colocalization with LAMP2 correlated well
with muscle protein synthesis (r = 0.751; P < 0.01, Figure
3D) and the body mass change of the last day (r = 0.630;
P < 0.01) in the untreated mice.
Figure 3 Decreased protein synthesis is associated with altered mTOR localization in the tumour-bearing mice at 11 days after C26 cell inoculation. (A)
Protein synthesis analysed by SUnSET in TA, diaphragm (DIA) and the heart (left) and the representative blots (right, C = CTRL, P = C26 + PBS,
Ab = C26 + sACVR/b, Ac = C26 + sACVR/c). (B) Quantification of mTOR-LAMP2 colocalization in TA and the representative images (scale bar = 10 μm).
Membranes were excluded from the analysis, but this did not have major impact on the results (data not shown). (C) Phosphorylation of rpS6 on
Ser240/244 in TA (left) and the representative blots (right). (D) Correlation between mTOR-LAMP2 colocalization and protein synthesis in CTRL and
C26 + PBS groups (Pearson correlation coefficient). * and ** = P < 0.05 and 0.01, respectively. Kruskall–Wallis with Holm–Bonferroni corrected
Mann–Whitney U (A, C); Student’s t-test (B, C26- and sACVR2B-Fc-effects). Lines without vertical ends show a pooled effect of all C26-groups com-
bined. N-sizes are depicted in the bar graphs.
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C26 cancer cachexia is associated with elevated
content of ubiquitinated proteins in skeletal muscle
The content of ubiquitinated proteins was slightly but sig-
nificantly increased in TA and diaphragm of the tumour-
bearing mice (Online Resource 4: Figure S3). In line with
this result, the mRNA expression of the major muscle-
specific E3 ubiquitin ligases Murf1 and Atrogin1 was mark-
edly increased in the tumour-bearing mice, similar trend
being observed also in recently characterized muscle ubiq-
uitin ligase of the SCF complex in atrophy-1 (Musa1)40
(Online Resource 4: Figure S3). sACVR2B-Fc administration
did not have significant effects on the markers of
ubiquitin–proteasome system (Online Resource 4: Figure
S3). Other protein degradation pathways may also contrib-
ute to muscle atrophy in tumour-bearing mice.
Indeed, our data suggests potentially increased autophagy
in tumour-bearing mice (Hentilä et al. unpublished
observations).
Reduced physical activity in C26 cancer cachexia is
not rescued by soluble ACVR2B and is associated
with minor alterations in skeletal muscle oxidative
properties
Home cage physical activity of the mice was recorded at
baseline and on Day 10 after the injection of cancer cells
or vehicle control. On Day 10, the tumour-bearing mice
were significantly less active compared with the control
mice, and sACVR2B-Fc administration had no effect on
the level of physical activity (Figure 4A). Reduced physical
activity was accompanied by minor decreases in citrate syn-
thase activity, but not in the markers of mitochondrial con-
tent in skeletal muscle and the heart of the tumour-bearing
mice compared with healthy controls (Figure 4B–E, Online
Resource 5: Figure S4). However, OXPHOS complex IV sub-
unit 1 (MTCO1) was increased in tumour-bearing mice in
both skeletal muscle and the heart (Figure 4D and 4E; On-
line Resource 5: Figure S4).
Increased circulating levels of pro-inflammatory
cytokines are not affected by blocking activin
receptor ligands
To investigate the possible effects of C26 cancer and
sACVR2B-Fc administration on circulating cytokines, a
multiplex assay was conducted. Of the 16 cytokines analysed,
the levels of pro-inflammatory IL-6 and monocyte
chemoattractant protein (MCP-1), also known as Chemokine
(C-C motif) ligand 2 (CCL2), were highly elevated
(P < 0.001) in the sera of the C26 mice while chemokine
RANTES (CCL5) was decreased from already low values of
the healthy mice (Online Resource 6: Table S2). The sACVR2B
treatment did not have any effect on IL-6 (P = 0.67) or on
Figure 4 Home cage physical activity and muscle oxidative properties at early phase of C26 cancer cachexia. (A) Activity indexes (AU) at baseline and at
Day 10 after C26 cell injection. N = 2–3 cages/group, 2 mice/cage. This result was replicated in the second short-term experiment (data not shown). (B)
Citrate synthase activities in TA, diaphragm, and the heart on Day 11 after C26 cell injection. (C) PGC-1α and cytochrome (Cyt) c, and (D) mitochondrial
OXPHOS protein content in TA on Day 11 after C26 cell inoculation. (E) Representative blots. * and ** = P < 0.05 and 0.01, respectively. C26-effect was
analysed by Student’s t-test (A, B), and group differences by Kruskall–Wallis with Holm–Bonferroni corrected Mann–Whitney U (C, D). N = 7–9/group.
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RANTES (P = 0.89), while it even further increased MCP-1
(P = 0.042), when the treatment was continued (Online Re-
source 6: Table S2). The treatment with sACVR2B-Fc also re-
sulted in slightly elevated serum IL-1β (P < 0.05)
independent of the treatment protocol, but its levels were
very close to the detection limit in most of the samples (On-
line Resource 6: Table S2).
Increased hepatic protein synthesis and acute
phase response in tumour-bearing mice are
partially blocked by soluble ACVR2B
Liver mass was unaltered by C26 tumour and the treatments
(Figure 5A). However, C26 tumour-bearing mice had signifi-
cantly increased liver protein synthesis (Figure 5B) supported
by increased phosphorylation of ribosomal protein S6, a
marker of mTOR signalling (Figure 5C). This cancer effect
was attenuated by sACVR2B-Fc administration independent
of the treatment protocol (Figure 5B and 5C). Administration
of sACVR2B-Fc alone in healthy mice did not affect liver pro-
tein synthesis as analysed from our previous experiment30
(data not shown).
In line with increased protein synthesis, the C26 tumour-
bearing mice had increased levels of fibrinogen and
serpinA3N compared to healthy controls together with the
increased phosphorylation of Stat3 indicating activation of
APR (Figure 5C). Increased Stat3 phosphorylation was
partially attenuated by sACVR2B-Fc administration (Figure
5C). The protein contents of fibrinogen and serpinA3N corre-
lated with the body mass loss during the last day in the
tumour-bearing mice (r = 0.659, P = 0.001, and
r = 0.845, P < 0.001, respectively).
C26 cancer associated splenomegaly is partially
prevented by soluble ACVR2B independent of
splenic myeloid-derived suppressor cells
C26 tumour-bearing mice treated with PBS had significantly
(over 2.5-fold) increased spleen mass compared with healthy
control mice, which was partially prevented by sACVR2B-Fc
administration independent of the treatment protocol
(Figure 6A). We replicated the experiment with all groups ex-
cept the discontinued sACVR2B-Fc treatment and showed
again the same effects (Online Resource 7: Figure S5). Analy-
sis of the spleen histology from this experiment revealed
well-organized and clear red and white pulp areas in the con-
trol mice whereas in the tumour-bearing mice, moderate
structural disorganization of the white pulp areas occurred,
especially in sACVR2B treated mice (Figure 6B). To identify
possible myeloid-derived suppressor cell (MDSC) expansion,
spleen tissue was more specifically labelled with antibodies
against GR-1 (LY-6C/G) and CD11b and the expression of
typical MDSC marker genes was analysed by qPCR.42 The
density of CD11b positive cells (count/area) was increased
Figure 5 Liver mass, protein synthesis and markers of acute phase response on Day 11 after C26 cell injection. (A) Liver mass normalized to the length
of the tibia (TL). (B) Liver protein synthesis (left) and representative blots (right). (C) Phosphorylation of rpS6 on Ser240/244 and Stat3 on Tyr705, and
protein contents of fibrinogen and serpinA3N in liver (left) and the representative blots (right). N = 6–9/group. ** and *** = P < 0.01 and 0.001, re-
spectively. Student’s t-test and one-way ANOVA with Holm–Bonferroni corrected LSD (A), Kruskall–Wallis with Holm–Bonferroni corrected Mann–
Whitney U (B, C). Lines without vertical ends in (C) show a pooled effect of both sACVR2B-Fc groups combined. N-sizes are depicted in the bar graphs.
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in the C26 tumour-bearing mice compared with the control
mice without changes in the density of GR-1 (LY-6C/G) pos-
itive cells (Figure 6C). As spleen size was increased in the
tumour-bearing mice, counts/area were multiplied by the
spleen mass to get an idea of the total abundance of
CD11b and GR-1 (LY-6C/G) positive cells. This analysis
showed a more pronounced increase in both CD11b and
GR-1 (LY-6C/G) positive cells in the tumour-bearing mice
(Online Resource 7: Figure S5).
The expression of genes previously related to presence
and development of MDSCs42 was increased in the
tumour-bearing mice, and this effect was even more pro-
nounced in the sACVR2B-Fc treated mice (Figure 6D–G).
These results suggest an increased abundance of splenic
MDSCs in the tumour-bearing mice, and this effect is even
accentuated by sACVR2B administration. Thus, changes in
MDSCs do not explain the effect of sACVR2B-Fc on the
spleen mass, and the cell population responsible for this
effect is still to be identified. Nevertheless, as a possible
mechanism, sACVR2B-Fc treated group showed increased
mRNA expression of Cyclin Dependent Kinase Inhibitor
1A (Cdkn1a/p21), an inhibitor of proliferation (Online Re-
source 7: Figure S5).
Activin receptor ligand blocking reverses the mild
anaemia observed in tumour-bearing mice
In the tumour-bearing mice, red blood cell count,
haemoglobin, and haematocrit were slightly, but signifi-
cantly decreased (Figure 7A–C). All of these parameters
were at least partially restored by sACVR2B-Fc administra-
tion (Figure 7A–C). In contrast, platelet count was robustly
augmented in the tumour-bearing mice independent of
Figure 6 Administration of sACVR2B-Fc attenuates C26 cancer-induced splenomegaly independent of splenic MDSCs. (A) Spleen mass normalized to
the length of the tibia (TL) on Day 11 after C26 cell injection. (B) Haematoxylin and eosin staining of the spleen on Day 13 after C26 cell injection. (C)
CD11b and GR-1 (LY-6C/G) count in spleen on Day 13 after C26 cell injection and representative immunofluorescence images. Scale bar = 100 μm. The
mRNA expression of MDSC markers (D) interleukin-10 (Il-10, (E) S100 calcium binding protein A8 (S100a8), and (F) the splice variant of X-box Binding
Protein 1 (Xbp1s) as well as (G) Interferon Regulatory Factor 8 (Irf8), a negative regulator of MDSCs,41 on Day 13 after C26 cell injection. *, **, and
*** = P < 0.05, 0.01, and 0.001, respectively. Student’s t-test and one-way ANOVA with Holm–Bonferroni corrected LSD (A, C, D), Mann–Whitney
U (E–G). Lines without vertical ends show a pooled effect of all C26-groups combined. N-sizes are depicted in the bar graphs. N = 7–9/group in (E–G).
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sACVR2B-Fc administration (Figure 7D). White blood cell
count tended to increase by continued sACVR2B-Fc admin-
istration (Figure 7E).
Discussion
In the present study, we show that preventing cachexia by
continued blocking of ACVR2B ligands improved survival in
tumour-bearing mice without affecting primary tumour
growth similarly as earlier.9,14,16 These findings together with
results from treatments affecting other pathways19–22 as well
as epidemiological evidence in humans2 have led to sugges-
tions for a possible causal link between preservation of mus-
cle mass and improved survival.4 This hypothesis is in part
supported by the present study showing that increasing mus-
cle mass and maintaining it by continued blocking of ACVR2B
ligands improves survival. In comparison, the discontinuation
of the treatment before the tumour formation led to a sys-
tematically worse outcome and also shorter survival. This
may be due to the fact that the discontinuation of the treat-
ment may in itself have adverse effects on the host or be-
cause larger muscles at the onset of the disease may result
in more robust cachexia, as shown earlier.43 Nevertheless, if
the preservation of muscle per se indeed improved survival,
the exact mechanisms still remain unresolved. It is possible,
for instance, that the preservation of some specific vital mus-
cles, such as the major respiratory muscles,44,45 is paramount
rather than muscle tissue in general. Indeed, diaphragm atro-
phy and weakness accompanied by ventilatory dysfunction
have been reported in C26 tumour-bearing mice.46,47 Inter-
estingly, ACVR2 ligand blocking restored diaphragm mass in
the present study, which may at least in part have explained
the prolonged survival of these mice, although the differ-
ences between the treatment protocols were quite marginal
at the time point investigated.
In addition to skeletal muscles, cardiac cachexia and asso-
ciated pathological changes such as arrhythmias may be
linked to survival in cancer cachexia.48,49 In our hands, how-
ever, the C26 tumour burden resulted in only mild cardiac ca-
chexia and sACVR2B treatment did not affect heart size,
similarly as earlier.35 This differs from the results of Zhou
et al. who reported significant cardiac atrophy which was fully
reversed by sACVR2B. This may be explained by more severe
cachexia that was treated with higher doses of sACVR2B-Fc.9
However, we have recently demonstrated that sACVR2B-Fc
has markedly smaller effects on cardiac than skeletal muscle
in chemotherapy-induced cachexia model.35 Future studies
should better elucidate the effects of blocking ACVR2 ligands
on the heart and the importance of cardiac cachexia on can-
cer prognosis.
Liver acute phase response (APR) has been associated with
impaired survival in cancer cachexia in humans.26 It is an
early-defence system driven by cytokines such as IL-6, which
induces Stat3 activation and consequently increased expres-
sion of acute phase proteins.26,50 We showed induced he-
patic APR in tumour-bearing mice supporting previous
Figure 7 Haematological parameters in C26 tumour-bearing mice and the effects of sACVR2B-Fc. (A) Red blood cell count (RBC), (B) haemoglobin, (C)
haematocrit, (D) platelet count, and (E) white blood cell count (WBC) on Day 11 after C26 cell injection. *, **, and *** = P < 0.05, 0.01 and 0.001,
respectively. Kruskall–Wallis with Holm–Bonferroni corrected Mann–Whitney U (A–C) or Student’s t-test and one-way ANOVA with Holm–Bonferroni
corrected LSD (D, E). N-sizes are depicted in the bar graphs. These results were replicated in the second short-term experiment (data not shown).
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findings.25 Also the liver protein synthesis was increased in
the tumour-bearing mice, a finding that is consistent with
an earlier study with C26 cancer,51 and also with human
cancer cachexia, assuming that increased synthesis of circu-
lating fibrinogen reflects mainly increased liver protein syn-
thesis.52 Increased liver protein synthesis in tumour-bearing
mice may reflect increased synthesis of exported APR pro-
teins, because no significant changes in liver mass were ob-
served in any of the experiments. Both ACVR2 ligand
blocking protocols reduced the increased protein synthesis
and Stat3 phosphorylation again without an effect on liver
mass. Although no differences in these results were ob-
served between the two treated groups, the discontinued
sACVR2B-Fc treatment was associated with much worse
prognosis perhaps arguing against these hepatic changes
being important for the survival benefit of continued
ACVR2 ligand blocking. Interestingly, however, the level of
hepatic APR proteins correlated with body mass loss sug-
gesting that the importance of these pathways should be
further investigated in the future as well as the mecha-
nisms of blocking ACVR2 ligands on liver protein synthesis
in cancer.
Pro-inflammatory cytokines are thought to be important
for the development of cancer cachexia53 and on its progno-
sis.27,54 Of multiple cytokines analysed, IL-6 and MCP-1 were
strongly elevated in the sera of the C26 tumour-bearing mice,
which is in agreement with previous findings in the same ex-
perimental model.9,20 In humans, high levels of MCP-127 and
IL-654 have been related to shorter survival time in pancreatic
ductal adenocarcinoma and lung cancer, respectively. Re-
cently, elevated MCP-1 was associated with cachexia in treat-
ment naïve pancreatic cancer patients.55 However, in the
present study, these responses were not attenuated by the
sACVR2B treatment suggesting that continued blocking of
ACVR2B pathway enhances survival and prevents muscle loss
independent of the elevated circulating pro-inflammatory cy-
tokines similarly as suggested by Zhou et al. based on IL-6, IL-
1β, and TNF-α.9 Continued sACVR2B-Fc treatment even in-
creased serum MCP-1 and IL-1β, but the mechanism and
physiological importance of this effect is unknown and fur-
ther studies are needed. We also analysed sera from the sur-
vival experiment at the day of euthanasia (n = 4–5 per
group), where MCP-1 was even further elevated in the
C26 + sACVR/c group of mice. This may be due to prolonged
survival and thus more advanced disease at euthanasia (data
not shown).
Interestingly, increased spleen size (splenomegaly) typi-
cally observed in experimental cancer,28,56,57 was attenuated
in sACVR2B-Fc treated mice. In addition, expansion of splenic
MDSCs has previously been associated with potential effects
on cachexia development and survival.28 Interestingly, al-
though the increase in spleen size was prevented, the
markers of MDSCs in spleen were not decreased with ACVR2
ligand blocking. Moreover, the increase in spleen size was
prevented by sACVR2B-Fc treatment independent of the
treatment protocol suggesting that spleen may not play a
major role in enhanced survival with the continued ACVR2
ligand blocking. Nevertheless, an overall reduction in red
pulp area by sACVR2B was recently observed in an animal
model of β-thalassemia intermedia, and this was associated
with alleviation of anaemia and splenomegaly.58 We found
that the white pulp areas were clearly visible in healthy
control mice, whereas in the tumour-bearing mice, these
areas were disorganized, and this tended to occur especially
in sACVR2B treated mice. We also found changes in basic
haematological parameters such as decreased blood
haemoglobin and haematocrit in C26 tumour-bearing mice,
which is in line with previous studies,59 and those were re-
versed in the sACVR2B treated mice. Importantly, however,
these factors did not differ between the treated groups, at
least at this time point where the loss of body mass had al-
ready started with the discontinued treatment, suggesting
that the attenuation of anaemia unlikely results in improved
survival with continued ACVR2 ligand blocking. However,
the effect of preventing anaemia per se may have other
benefits as erythropoietin can improve health in C26
tumour-bearing mice.24,60
Physical activity has been shown to be beneficial for
health and also for cancer incidence and potentially for tu-
mour host survival.61,62 Our results showed that tumour-
bearing mice were less active than healthy controls
supporting earlier evidence of decreased physical activity in
tumour-bearing mice.16,59,63 Decreased physical activity was
not due to muscle wasting per se as preventing muscle
wasting by blocking ACVR2 ligands did not prevent the de-
crease in physical activity. Our results also argue against
physical activity being an important factor for improved sur-
vival with continued sACVR2B-Fc treatment. Similar results
of the effects of sACVR2B treatment on physical activity have
been reported earlier in LLC tumour-bearing mice.16 The re-
duction in physical activity was associated with only minor
changes in some of the mitochondrial markers in skeletal
muscle and the heart.
Similarly to Zhou et al.,9 we report that sACVR2B-Fc did not
affect C26 tumour mass showing that C26 tumour growth is
not regulated by ACVR2 ligands. We extended this finding
by showing that the gene expression of Activin A and Il-6,
which are important proteins in cachexia,8 were not reduced
by sACVR2B-Fc further showing that sACVR2B-Fc improved
survival in this experimental model of cancer without
marked effects on the tumour. However, the circulating
ACVR2 ligands may also be directly or indirectly related to
the cancer prognosis at least in part independent of ca-
chexia. High circulating Activin A levels predict poor progno-
sis in colorectal and lung cancer patients.10,64 This may be
explained by increased Activin A levels reflecting the severity
or the extent of the cancer or cachexia. However, also direct
effects of Activin A,65,66 and perhaps of other ACVR2 ligands,
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on non-muscle tissues may also affect survival in cancer ca-
chexia, and thus more studies are needed to further investi-
gate this phenomenon.
Muscle wasting in cancer cachexia can be attributed to de-
creased protein synthesis,5,6 impaired regeneration7 as well
as increased protein degradation6 in skeletal muscle. At the
time point in which body mass loss started to accelerate
and predicted survival, increased mRNA expression of muscle
specific E3 ubiquitin ligases and the content of ubiquitinated
proteins were observed, suggesting increased protein degra-
dation via the ubiquitin-proteasome system. At the same
time, robustly decreased muscle protein synthesis in TA,
diaphragm, and the heart of the tumour-bearing mice was
observed. In the present study, as predicted from decreased
mTOR signalling activity, mTOR colocalization with the
lysosomes/late-endosomes was decreased in skeletal mus-
cles of C26 tumour-bearing mice. Interestingly, our correla-
tion data suggests that this novel finding may explain at
least in part the cachexia and decreased muscle protein syn-
thesis in the untreated tumour-bearing mice. Targeting of
mTOR to lysosomes/late-endosomes has previously been
shown to be sufficient to activate mTOR signalling while
mTOR inactivation by, e.g. amino acid starvation is associ-
ated with mTOR dissociation from lysosomes/late-
endosomes.38,39 Even though continued sACVR2B-Fc admin-
istration had no effect on protein synthesis at this time
point, it was able to partially restore S6 phosphorylation
and the colocalization of mTOR with the lysosomes/late-
endosomes. The reason for this discordance is unknown,
but may be due to decreased food intake or simply the re-
fractory nature of cancer cachexia at this time point in most
of the animals.67 Indeed, the increased skeletal muscle
masses with ACVR2B ligand blocking are probably due to
earlier changes in protein synthesis and/or degradation, as
we have previously reported increased protein synthesis
with ACVR2B ligand blocking in healthy and chemotherapy
receiving mice.15,30
In conclusion, we showed that increased muscle size with
ACVR2 ligand blocking was associated with improved survival
in C26 tumour-bearing mice only when the treatment was
continued after the tumour formation. The prolonged sur-
vival could potentially be attributed in part to maintenance
of muscle mass and, in theory, the respiratory muscle mass.
However, more specific strategies in preventing total and
specific loss of muscle (limb, respiratory, and heart) without
possible non-muscle effects should be investigated in the
future. Moreover, our results suggest that circulating pro-
inflammatory cytokines, physical activity, or altered hepatic
and splenic physiology may not be determining factors for
improved survival with activin receptor ligand blocking. In ad-
dition, our novel result of decreased muscle protein synthesis
and mTOR localization with lysosomes/late endosomes opens
up possible future research questions and treatment options
for cachexia.
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Figure S1 C26 cancer decreases (a) body mass (time x group
interaction P < 0.001) and masses of (b) tibialis anterior
(TA), (c) gastrocnemius (GA), (d) heart and (e) epididymal
fat (eWAT). TL = tibial length. C26 tumour expresses substan-
tially higher levels of (f) Activin A, (g) Il-6, and (h) Myostatin
mRNA than LLC tumour. *, ** and *** = P < 0.05, P < 0.01
and P < 0.001, respectively. Students t-test (a–e), Mann-
Whitney U (f–h). N-sizes are depicted in the bar graphs, ex-
cept in (a) where N = 8 per group. Data is presented as means
± SEM, except in (a), where data is presented as mean ± SD.
Supplementary Table S1 Primer information for qPCR anal-
yses.
Figure S2 The effects of C26 cancer and sACVR2B-Fc admin-
istration on body mass and tumour and muscle gene ex-
pression. (a) Length of the tibia on day 11 after C26 cell
inoculation. (b) Body masses in the survival experiment. Tu-
mour (c) Activin A (Inhibin βA) and (d) Il-6 mRNA expres-
sion. Gastrocnemius (e) Activin A (Inhibin βA), (f) Il-6 and
(g) Myostatin (Gdf8) mRNA expression at day 11 after tu-
mour inoculation. C26 cells were inoculated at day 0.
mRNA-results were normalized to 36b4 mRNA. FC = fold
change. * and ** = P < 0.05, and P < 0.01, respectively.
Student’s t-test and one-way ANOVA with Holm-Bonferroni
corrected LSD (a, e–g). Kruskall-Wallis with Holm-Bonferroni
corrected Mann-Whitney U (c, d). N-sizes are depicted in
the bar graph except in (b) in which n = 6, 12, 8, and 9
in CTRL, C26 + PBS, C26 + sACVR/b, and C26 + sACVR/c, re-
spectively.
Figure S3 (a) Phosphorylation of S6K1 at Thr389 was de-
creased in tumour-bearing mice on day 11 after C26 cell in-
oculation. C26 cancer cachexia was associated with
increased ubiquitinated proteins in (b) tibialis anterior and
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(c) diaphragm, and increased mRNA expression of ubiquitin
ligases (d) Murf1, (e) Atrogin1 and (f) Musa1, which were
not affected by sACVR2B-Fc administration in gastrocne-
mius on day 11 after C26 cell inoculation. C = CTRL, P =
C26 + PBS, Ab = C26 + sACVR/b, Ac = C26 + sACVR/c. FC
= fold change. * and ** = P < 0.05 and P < 0.01, respec-
tively. Kruskall-Wallis with Holm-Bonferroni corrected
Mann-Whitney U (a–e), Student’s t-test and one-way
ANOVA with Holm-Bonferroni corrected LSD (f). N-sizes
are depicted in the bar graphs.
Figure S4 Mitochondrial markers in the heart on day 11 af-
ter C26 cell injection. (a) PGC-1α and cytochrome c (Cyt c)
protein levels were not altered by the C26 tumour or the
sACVR2B-Fc treatment in the heart. N-sizes are depicted
in the bar graphs. (b) OXPHOS complex IV (MTCO1) was
significantly increased in the hearts of the vehicle treated
tumour-bearing mice (C26 + PBS). In addition, when all
C26 tumour-bearing groups were pooled, a significant in-
crease was seen also in complexes CI (NDUFB8) and CIII
(UQCRC2) as well as the sum of all complexes (total). This
pooled C26-effect is depicted by the lines without vertical
ends. N = 7–9/group. C = CTRL, P = C26 + PBS, Ab = C26
+ sACVR/b, Ac = C26 + sACVR/c. * and *** = P < 0.05
and P < 0.001, respectively (Mann-Whitney U).
Supplementary Table S2 Serum cytokine levels at 11 days
after C26 cell injection. N = 8, 7, 6 and 8 in CTRL, C26 +
PBS, C26 + sACVR/b and C26 + sACVR/c groups, respec-
tively. The values are presented in pg/ml. If over half of
the values in the group were below or close to the detec-
tion limit, the concentration is not presented (depicted as
N/A in the table). Cytokines with at least 3/4 of all values
below or close to the detection limit are not shown (IL-
1a, IL-2, IL-3, IL-4, IL-10, IL-17, IFNy, TNF-α, MIP-1a and
GM-CSF). In statistical analysis, the C26-effect was analysed
by pooling all the tumour-bearing groups. The sACVR-effect
P-value designates the lowest sACVR2B-Fc P-value in com-
parison to C26 + PBS and if the significance is found, the
sACVR2B-Fc group significantly different compared with
C26 + PBS is indicated with *.
Figure S5 Effects of C26 tumour and sACVR2B-Fc on the
spleen on day 13 after C26 cell inoculation. (a) C26 can-
cer-induced splenomegaly is attenuated by sACVR2B-Fc ad-
ministration. Splenic (b) CD11b and (c) GR-1 contents were
increased in C26 cancer when multiplied by spleen mass to
reflect the total abundance of CD11b and GR-1 positive
cells. (d) sACVR2B-Fc administration resulted in increased
splenic Cdkn1a (p21) mRNA. * and ** = P < 0.05 and P
< 0.01, respectively. C26 and sACVR2B-Fc effects were
analysed with Student’s t-test (a, b, d) or Mann-Whitney
U test (c). N-sizes are depicted in the bar graphs.
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